Download Files:
Oprozomib
$75 – $792
Products Details
Product Description
– Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells[1].
Web ID
– HY-12113
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H32N4O7S
References
– [1]Han-Jie Zhou, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009 May 14;52(9):3028-38.|[2]Dharminder Chauhan,et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.|[3]M A Hurchla, et al.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013 Feb;27(2):430-40.
CAS Number
– 935888-69-0
Molecular Weight
– 532.61
Compound Purity
– 99.71
SMILES
– C[C@]1(OC1)C([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@@H](NC(C3=CN=C(C)S3)=O)COC)=O)COC)=O)=O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : ≥ 50 mg/mL
Target
– Apoptosis;Autophagy;Proteasome
Pathway
– Apoptosis;Autophagy;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
